Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sanofi-Aventis Bristol-Myers Squibb |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00335673 |
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Irbesartan (Aprovel) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Irbesartan in Mild to Moderate Hypertensive Patients |
Enrollment: | 1754 |
Study Start Date: | February 2006 |
Primary Completion Date: | November 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 30 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Responsible Party: | sanofi-aventis ( Medical Affairs Study Director ) |
Study ID Numbers: | IRBES_L_00165 |
Study First Received: | June 9, 2006 |
Last Updated: | May 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00335673 |
Health Authority: | Egypt: Ministry of Health and Population |
Irbesartan Vascular Diseases Angiotensin II Hydrochlorothiazide Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |